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Abstract

Date of submission: May 16, 2022

Neurosteroids are rapidly emerging as important new therapies in neuropsychiatry, with one such
agent, brexanolone, already approved for treatment of postpartum depression, and others on the
horizon. These steroids have unique properties, including neuroprotective effects that could benefit
a wide range of brain illnesses including depression, anxiety, epilepsy, and neurodegeneration. Over
the past 25 years, our group has developed ex vivo rodent models to examine factors contributing
to several forms of neurodegeneration in the retina. In the course of this work, we have developed
a model of acute closed angle glaucoma that involves incubation of ex vivo retinas under hyperbaric
conditions and results in neuronal and axonal changes that mimic glaucoma. We have used this model
to determine neuroprotective mechanisms that could have therapeutic implications. In particular,
we have focused on the role of both endogenous and exogenous neurosteroids in modulating the
effects of acute high pressure. Endogenous allopregnanolone, a major stress-activated neurosteroid
in the brain and retina, helps to prevent severe pressure-induced retinal excitotoxicity but is
unable to protect against degenerative changes in ganglion cells and their axons under hyperbaric
conditions. However, exogenous allopregnanolone, at a pharmacological concentration, completely
preserves retinal structure and does so by combined effects on gamma-aminobutyric acid type A
receptors and stimulation of the cellular process of macroautophagy. Surprisingly, the enantiomer
of allopregnanolone, which is inactive at gamma-aminobutyric acid type A receptors, is equally
retinoprotective and acts primarily via autophagy. Both enantiomers are also equally effective
in preserving retinal structure and function in an in vivo glaucoma model. These studies in the
retina have important implications for the ongoing development of allopregnanolone and other
neurosteroids as therapeutics for neuropsychiatric illnesses.
Key Words: allopregnanolone; autophagy; enantiomers; excitotoxicity; gamma-aminobutyric acid
type A receptors; glaucoma; optic nerve; oxysterols
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Introduction
Neurosteroids are important modulators of neuronal stress and use a variety
of mechanisms to help neurons establish homeostasis following insults.
Neurosteroids are synthesized endogenously in the brain from cholesterol or
sterol precursors, and are a subset of a broader class of steroids that modulate
brain function, referred to as neuroactive steroids (NAS) (Paul and Purdy,
1992). Increasing evidence indicates the importance of NAS as therapeutics
for neuropsychiatric illnesses (Zorumski et al., 2013), and has led to FDA
approval of brexanolone, for treatment of postpartum depression (MeltzerBrody and Kanes; 2020). Brexanolone is a formulation of the neurosteroid,
allopregnanolone (AlloP), in cyclodextrin (Captisol) for intravenous infusion.
Another NAS, zuranolone, is in late-stage human trials for postpartum
depression and major depression (Gunduz-Bruce et al., 2019; Deligiannidis
et al, 2021). The approval of brexanolone has prompted increasing interest
in understanding mechanisms contributing to the action of AlloP and related
NAS. For over 25 years, our group has examined models of neuronal injury
and stress in retinal preparations and these studies provide new insights
into the actions of AlloP as both an endogenous stress modulator and as a
pharmacological therapeutic. In this review, we describe our studies in the
retina, with emphasis on glaucoma models, and ways in which this work may
inform use of NAS in neuropsychiatry.

Search Strategy and Selection Criteria
This review focuses upon work done in our laboratories over an extended
period that includes the development of an ex vivo retinal preparation for
studying various forms of retinal degeneration including extension to a
model of glaucoma. To put this work in context of the field, our review of
the literature used PubMed as the search engine with search terms that

included retina, glaucoma, neurosteroids, and excitotoxicity, focusing on work
pertinent to the experiments described.

Relevance of the Retina and Glaucoma to
Neuropsychiatry
Multiple neuropsychiatric illnesses involve changes in axons and white matter
in the brain. These include neurodegenerative illnesses such as Alzheimer’s
and Huntington’s diseases, but also primary psychiatric illnesses including
schizophrenia, major depression, and autism, among others (Fields, 2008;
Alnaes et al., 2018). Axonal changes contribute to altered connectivity
within and across brain regions underlying mental functions of cognition,
emotion, and motivation, and can be observed early in the course of illness,
particularly in disorders with developmental origins. Given that glaucoma
involves damage to retinal ganglion cells (RGCs) and their axons that form
the optic nerve, glaucoma could provide insights into understanding axonal
dysfunction and its treatment. Glaucoma is the second leading cause of
blindness worldwide and the number one cause of blindness among African
Americans. Glaucoma is also associated with more than two-fold increase in
major depression (Yoshikawa et al., 2019).
A second reason for interest in the retina involves increasing evidence
that RGCs mediate effects of light on mood and behavior, including risk of
depression. It is now clear that there are multiple subtypes of RGCs, including
RGCs that express melanopsin and have intrinsic photosensitivity (ip) akin to
photoreceptors (Tran et al., 2019). Different subtypes of ipRGCs connect to
different subcortical regions and mediate unique behavioral effects (Fernandez
et al., 2018; Do, 2019). One subclass connects to the suprachiasmatic
nucleus and secondarily to the hippocampus, mediating effects of light
on learning and memory (Fernandez et al., 2018; Huang et al., 2021). A
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second subtype connects to the perihabenular region and secondarily to the
dorsomedial striatum and nucleus accumbens to mediate effects of light on
mood (Fernandez et al., 2018; Huang et al., 2019). Other studies indicate
that ipRGCs drive a light-activated pathway to ventral lateral geniculate and
the intergeniculate leaflet that results in inhibition of lateral habenula and
mediates antidepressant effects of light, a finding of importance for seasonal
mood disorders and disorders of circadian rhythms (Huang et al., 2019).

An Ex Vivo Retinal Preparation and Glaucoma
Model
Work in the retina has had a major impact on understanding mechanisms
of neurodegeneration, particularly glutamate-mediated excitotoxicity. Some
of the earliest work on glutamate toxicity came from observations in the
retina (Lucas and Newhouse, 1957) and was later extended to the brain by
John Olney (Olney, 1969). In the 1980s, Olney and colleagues used an ex
vivo embryonic chick retinal preparation to define mechanisms underlying
glutamate-induced excitotoxicity (Olney et al., 1986, 1990; Romano et al.,
1998). Because of limitations of the chick model including challenges in doing
studies across a range of ages, Yukitoshi Izumi developed an ex vivo model
for these studies using rat retinas (Izumi et al., 1995a). This model proved
useful for histological studies across a range of developmental ages (Izumi et
al., 1995b) including work on the effects of excitotoxic conditions on Muller
glial cells (Izumi et al., 2003) and the role of glutamate transporters (Izumi et
al. 2002). Other studies examined the mechanisms of various forms of retinal
phototoxicity (Tokuda et al., 2007, 2009).
In the early 2000s, Makoto Ishikawa and colleagues adapted the ex vivo rat
preparation to study the effects of elevated pressure as a model of acute
closed angle glaucoma. The initial model incubated retinas under conditions
designed to mimic acute increases in hydrostatic pressure. For these studies,
retinal eye cups from 30-day-old rats were incubated at the bottom of
cylinders filled to varying degrees with oxygenated artificial cerebral spinal
fluid (ACSF) to mimic normal pressure (10 mmHg), moderately elevated
pressure (35 mmHg) and high pressure (75 mmHg) (Ishikawa 2010; Figure
1). Retinas incubated under normobaric conditions exhibited intact retinal
histology with no evidence of damage. However, retinas incubated for 24
hours at 75 mmHg exhibited damage to RGCs (shrinkage) and swollen axons of
these neurons without significant injury to other retinal layers (Ishikawa et al.,
2010, 2011). Damage to the optic nerve head was also observed. Importantly,
damage caused by high pressure differed distinctly from excitotoxic damage
produced by glutamate or AMPA under normobaric conditions (Ishikawa et al.,
2010), and was histologically distinct from the effects of simulated ischemia
(oxygen-glucose deprivation) (Izumi et al., 2003; Figure 2). Nonetheless,
damage to RGCs and axonal swelling resulting from hyperbaric incubation
was blocked completely by a combination of glutamate receptor antagonists
acting at NMDA and non-NMDA ionotropic receptors (Ishikawa et al., 2010).
The initial glaucoma model described above was an open hydrostatic system
in which pressure on the retinal eyecups was controlled by the height of
fluid in the incubation cylinders. This model had several limitations and was
eventually replaced by a closed incubation system in which volume in the
chamber was kept constant and pressure was regulated by influx and efflux of
gas (95% oxygen-5% carbon dioxide) via separate valves, using a manometer
to monitor intra-chamber pressure (Ishikawa et al., 2016; Figure 1). Retinas
were incubated in standard volumes of ACSF for 24 hours and showed similar
changes in RGCs and axons in response to hyperbaric pressure without
damage to other retinal layers.

Neurosteroids and Effects of High Pressure in
the Retina
Why neurosteroids?
Neurosteroids, including AlloP, are synthesized locally from cholesterol in
excitatory neurons and glia cells in response to a variety of stressors. In the
hippocampus, these stressors include metabolic insults (altered energy
metabolism) and toxins (ethanol and acetaldehyde) along with the stress
hormone, corticosterone (Zorumski and Izumi, 2012; Zorumski et al., 2014).
Importantly these stressors cause acute accumulation of glutamate and tonic
activation of NMDA receptors (Tokuda et al., 2011). Even brief exposures
to these stressors (5–30 minutes) cause untimely activation of NMDA
receptors and, as a result, impair induction of long-term potentiation (LTP)
in the CA1 hippocampal region through an NMDA receptor-mediated form
of metaplasticity (Zorumski and Izumi, 2012). These changes occur in the
absence of histological damage or changes in baseline synaptic transmission,
but involve upregulation of the synthesis of 5-alpha reduced neurosteroids,
particularly AlloP. These observations, coupled with the role of cellular
stress (high pressure) and glutamate in the glaucoma model, led us to
consider whether AlloP and other sterols might be important modulators
of stress on retinal structure and function, serving perhaps as homeostatic
neuroprotective mechanisms. Furthermore, the retina is neurosteroidogenic
and RGCs express key enzymes in neurosteroid synthesis including CYP11A1,
a mitochondrial cholesterol side chain cleavage enzyme that generates
pregnenolone as the first step in neurosteroid synthesis (Guarneri et al., 1994,
1998, 2003; Cascio et al., 2015). RGCs express other steroidogenic proteins
including the 18 kDa translocator protein, TSPO, as well as 5-alpha reductase
(5AR), a key synthetic enzyme (Ishikawa et al., 2016).

Neurosteroids as neuroprotectants
Because of the therapeutic potential of AlloP and other NAS, we initially
examined whether exogenous AlloP alters injury to RGCs and axons in the
nerve fiber layer (NFL). Co-incubation of retinas for 24 hours with high
pressure and varying concentrations of AlloP resulted in concentrationdependent retinal protection. At 10 nM AlloP, there was no clear change
in pressure-induced damage; some neuroprotection was observed at 100
nM, with complete retinal preservation at 1 µM (Ishikawa et al., 2014), a
concentration above physiological levels.
In related studies, we examined the role of endogenous AlloP in modulating
effects of high pressure. Using liquid chromatography and tandem mass
spectrometry to measure AlloP, we found very low levels of the steroid
under basal conditions when retinas were incubated for 24 hours at 10 mm
Hg. At 35 mm Hg, only marginal increases of AlloP were observed, while
incubation at 75 mm Hg resulted in 60–70-fold increases in AlloP compared
to normobaric conditions (Ishikawa et al., 2014). These increases in AlloP
at high pressure were partially inhibited (approximately 50% reduction) by
finasteride, a 5AR antagonist that acts at a subset of 5ARs. More complete
inhibition was observed with dutasteride, a broader spectrum 5AR antagonist
(Pinacho-Garcia et al., 2020), and with the competitive NMDA receptor
antagonist, 2-amino-5-phosphonovalerate (Ishikawa et al., 2014). Using an
antibody against 5-alpha-reduced steroids that primarily recognizes AlloP
(Tokuda et al., 2010, 2011), we also observed immunohistochemical evidence
of increases in neurosteroids in RGCs; these changes were dampened by the
antagonists described above (Ishikawa et al., 2014).
Changes in neurosteroid levels led us to consider whether endogenous
5-alpha-reduced steroids play a protective role in the retina under stress.
When retinas were incubated with 5AR antagonists under normobaric
conditions, no significant histological changes were observed. However, 5AR
antagonists led to marked damage in multiple retinal layers during exposure
to high pressure. These latter changes included RGC and axonal damage as
well as excitotoxic changes in other retinal layers. Excitotoxic changes included
marked swelling of neurons resulting in “bulls-eye” appearances of cells in
the inner nuclear layer (INL) and “Swiss-cheese” (edematous) changes in the
inner plexiform layer. This severe excitotoxicity was blocked by the NMDA
receptor antagonist, 2-amino-5-phosphonovalerate, and by exogenous AlloP
at 1 µM (Ishikawa et al., 2014).
We also found that high pressure increases expression of genes and
proteins thought to be involved in neurosteroidogenesis, including TSPO
and 5AR. Increases in 5AR, mostly type II, a form of the enzyme inhibited by
dutasteride and finasteride (Pinacho-Garcia et al., 2020), were observed in
RGCs and INL (Ishikawa et al., 2016), consistent with what we observed with
changes in AlloP levels described above. TSPO has a complex relationship to
steroidogenesis. While it is clearly a protein of importance for mitochondrial
function, its role in neurosteroid synthesis is less certain based on studies in
TSPO knockout mice (Selvaraj et al., 2015), although other studies suggest
some role in neurosteroidogenesis (Tokuda et al., 2010; Ishikawa et al., 2016;
Mages et al., 2019).
How is AlloP neuroprotective? Roles of gamma-aminobutyric acid-A
receptors and autophagy
AlloP is a complex neuromodulator produced on-demand under stressful
conditions in the brain and nervous system. It has several known mechanisms
that could contribute to neuroprotection. Most prominently, AlloP is a potent
and effective positive allosteric modulator (PAM) of gamma-aminobutyric acid
(GABA)-A receptors, the receptors that mediate the majority of fast inhibitory
transmission (Zorumski et al., 2019). Potentiation of GABA-A receptors
occurs at mid-nanomolar concentrations; at higher nanomolar to micromolar
concentrations, AlloP can directly open GABA-A channels in the absence of
GABA (called direct channel gating). GABA-A receptors are heteropentamers
with 19 subunits identified (Belelli and Lambert, 2005). Different subtypes
of GABA-A receptors are expressed at synapses where they mediate phasic
forms of inhibition. Other GABA-A receptors are expressed at extrasynaptic
sites where they sense ambient levels of GABA and mediate tonic inhibition
(Belelli et al., 2009). Importantly, AlloP and related NAS modulate both phasic
and tonic inhibition, giving them the unique ability to regulate the balance
of excitation and inhibition throughout the brain. Thus, modulation of GABA
transmission is a major mechanism likely contributing to the effects of AlloP.
Beyond GABA, AlloP also has effects on other ion channels and intracellular
processes. These include inhibition of low voltage-activated (T-type) calcium
channels that mediate burst firing in certain neurons and help to regulate
oscillatory firing and pain (Pathirathna et al., 2005). AlloP is a highly lipophilic
steroid and accesses intracellular compartments where it modulates
inflammation (Balan et al., 2019, 2021), mitochondrial function, and energy
utilization (Grimm et al., 2014).
We examined the role of GABA-A receptors in the effects of AlloP in our
glaucoma model using picrotoxin, a non-competitive GABA-A receptor
antagonist. The protective effects of exogenous AlloP were completely
blocked by co-administration of picrotoxin, indicating a prominent role for
GABA-A receptors in neuroprotection. In addition to overcoming protection
of RGCs and axons in the NFL, picrotoxin promoted more severe damage in
the retina including excitotoxic changes in the INL and inner plexiform layer
(Ishikawa et al., 2014).
Because neuroprotective effects of AlloP in other studies involve mechanisms
in addition to GABA-A receptor modulation (Langmade et al., 2006), we also
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Torin 2, produced partial protection against high pressure, consistent with a
protective role of autophagy in our model (Ishikawa et al., 2021).
Taken together, these results indicate that effects on GABA-A receptors and
activation of autophagy contribute to retinal protection by AlloP in the ex
vivo glaucoma model (Figure 3). Whether other actions of AlloP contribute to
retinal preservation remains uncertain, but are areas for further investigation.

Figure 3 ｜ AlloP and effects of high pressure on the retina.
The diagram depicts findings described in this paper including the role of stress (high
pressure), glutamate, NMDARs and synthesis of endogenous AlloP. Full protection by
exogenous AlloP and ent-AlloP, and the roles of GABA-A receptors and autophagy are
also depicted. The dashed arrow indicates that other mechanisms likely contribute
to the pathophysiology of glaucomatous changes. 5AR: 5 Alpha reductase; AlloP:
allopregnanolone; Ent-AlloP: enantiomer of allopregnanolone; GABA-ARs: GABA-A
receptors; NMDARs: N-methyl-D-aspartate receptors; RGC: retinal ganglion cells.
Figure 1 ｜ The diagram depicts methods for ex vivo rat retinal studies including the
methods used to mimic glaucoma.
Steps in the procedure are outlined. (1) An eye is removed from the orbits of a
decapitated rat. (2) The eye is placed in a holding device on the fixed floor of a petri dish
filled with chilled artificial cerebral spinal fluid. (3) The anterior segments and vitreous
are carefully removed. (4) The eyecup (retina and sclera) is positioned at the bottom of a
tall glass cylinder filled with artificial cerebrospinal fluid for 24 hours. The bottom of the
chamber is bathed at 30°C. (5) Alternatively, the eyecup in gassed artificial cerebral spinal
fluid is placed in a closed pressure-loading chamber for 24 hours.

A

B

C

Figure 2 ｜ Retinal histology in the ex vivo model.
(A) A control retina from a postnatal day 30 rat, incubated in artificial cerebral spinal
fluid at 30°C for 24 hours shows largely intact structure. (B) Incubation at 75 mmHg for
24 hours results in marked axonal swelling in the retinal ganglion cell layer (bottom).
(C) In contrast, incubation for 1 hour in a simulated ischemia condition (oxygen-glucose
deprivation) results in severe excitotoxic damage characterized by bulls-eye appearances
in the INL and Swiss-cheese-like changes in the IPL. Scale bar: 50 µm. GCL: Ganglion cell
layer; INL: inner nuclear layer; IPL: inner plexiform layer; OLM: outer limiting membrane;
ONL: outer nuclear layer; OPL: outer plexiform layer. Unpublished data.

examined whether alternative mechanisms contribute to effects in the retina
focusing on the possible role of macroautophagy (autophagy). Autophagy is
a mechanism by which cells recycle debris to help control stress responses,
preserve energy and promote survival, although, when unchecked, excessive
autophagy can also lead to cell death (Kroemer et al., 2010; Zhou et al., 2019).
Under hyperbaric conditions, AlloP increased levels of the lipidated form of
microtubule-associated protein 1 light chain 3 beta (LC3B-II) and decreased
levels of sequestosome 1 (p62), consistent with enhancement of autophagy.
At the ultrastructural level, AlloP increased the number of autophagosomes
and degenerative autophagic vacuoles in the NFL. Inhibitors of autophagy,
including bafilomycin A1 and SAR405, overcame the protective effects of AlloP
and induced severe neurodegeneration. Autophagy activators, rapamycin and

The enantiomer of AlloP is also neuroprotective in the retina
In an effort to determine the importance of GABA-A receptor PAM activity
in neuroprotection by AlloP, we used its unnatural enantiomer (ent-AlloP).
Earlier work demonstrated that effects of AlloP on GABA-A receptors
are highly enantioselective with the enantiomers differing by at least an
order of magnitude in potency (Wittmer et al., 1996; Covey et al., 2001).
However, enantiomers accumulate identically in cell membranes and
intracellular compartments (Chisari et al., 2009, 2010; Jiang et al., 2016). To
our surprise, but consistent with a prior study in a model of developmental
neurodegeneration (Langmade et al., 2006), we found that ent-AlloP was
at least as effective as AlloP in protecting the retina from damage produced
by high pressure at an equimolar concentration (1 µM). Furthermore, and
consistent with its lack of effects on GABA-A receptors, retinal protection by
ent-AlloP was not altered by picrotoxin, unlike natural AlloP (Ishikawa et al.,
2022). However, ent-AlloP increased the number of autophagosomes and
degenerative autophagic vacuoles in the NFL, and enhanced protein levels
of LC3B-II while decreasing levels of p62, indicating that ent-AlloP, like AlloP,
promotes autophagy. The autophagy inhibitor, 3-methyladenine, blocked
neuroprotection by ent-AlloP, but did not alter protection by AlloP. This latter
result is intriguing and suggests that it is possible to dissociate the role of
GABA-A receptors (or other mechanisms) from autophagy in the effects of
natural AlloP. Furthermore, these results indicate that ent-AlloP promotes
autophagy as a major mechanism of retinal protection, but these effects are
independent of GABA-A receptors in contrast to AlloP (Figure 3). In direct
comparisons using biochemical markers of autophagy, ent-AlloP appears to
be more effective than AlloP in activating autophagy at a concentration of
each that is fully neuroprotective (Ishikawa et al., 2022). We note that there
is presently controversy concerning the role of autophagy in glaucoma and
other neurodegenerative illnesses (Spalding et al., 2005; Kroemer et al.,
2010), but there is considerable interest in whether agents targeting this
mechanism can be developed for use in neuropsychiatric illnesses (Hui et al.,
2021). Additionally, the targets and mechanisms by which NAS stimulates
autophagy remain undefined, and it is presently unclear whether autophagy
is a primary action or the result of another modulated cellular process.
AlloP enantiomers are protective in an in vivo glaucoma model
To determine whether effects observed in the ex vivo glaucoma model
translate to animals, we used a rat model of increased intraocular pressure
(IOP) produced by intracameral injection of polystyrene microbeads. In this
model, IOP increases from about 10 mmHg to 30 mmHg over 3 days after
bead injection and IOP remains elevated at this level for the remainder of the
three-week experiment (Ishikawa, 2021, 2022). In control rats, elevated IOP
results in damage to RGCs and axons in the NFL by 21 days after injection.
Animals also exhibit impaired visual responses as measured by the retinal
scotopic threshold response. Effects of AlloP and ent-AlloP were examined
using a single injection of the steroids on day 7 after bead injection, at a time
when elevated IOP was fully established. The steroids were solubilized in
β-cyclodextrin and administered as a 1 µL injection into the vitreous using a
0.05% (w/v) saline solution. Neither steroid altered the increase in IOP caused
by microbead injections. Nonetheless, both enantiomers produced strong
neuroprotection based on histology and measures of apoptosis of RGCs, and
both promoted autophagy based on measures outlined in the ex vivo studies
above. Similarly, both steroids preserved the retinal scotopic threshold
response, indicating preserved visual function as well as histology (Ishikawa et
al., 2021, 2022).
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Lessons Learned from the Retina
Studies in the retina raise several important considerations for therapeutic
use of neurosteroids in neuropsychiatric illnesses. Below we outline several
key points that we take from the studies described. We provide additional
commentary for certain points that may be relevant to considering how
neurosteroids are used clinically going forward.
1. Rodent retinal models are useful for understanding mechanisms
contributing to neurodegeneration and neuroprotection. In particular, the ex
vivo system provides a useful tool for detailed mechanistic studies.
2. Neurosteroids, particularly AlloP, are important endogenous modulators
that help to preserve neuronal structure and function under stressful
conditions. This is likely true throughout the brain as it is in the retina.
3. Extracellular glutamate accumulation and tonic activation of NMDA
receptors are key drivers of the effects of stress on synthesis of neurosteroids.
This has been observed in both retina and hippocampus.
4. Removal of acute protection by endogenous 5-alpha reduced steroids
renders neurons highly vulnerable to excitotoxic neurodegeneration involving
multiple retinal layers. However, there are limits on neuroprotection provided
by endogenous AlloP, as evidenced by glaucomatous changes even in the
presence of increases in endogenous neurosteroid.
5. Pharmacological effects of neurosteroids are required for full
neuroprotection, even in the presence of elevated endogenous steroid levels.
These pharmacological effects may require concentrations above those that
are considered physiological as evidenced by full protection with 1 µM but
not 100 nM exogenous AlloP. Furthermore, a single injection of neurosteroid
at a pharmacological dose can have lasting neuroprotective effects in vivo
even when the primary neuronal stressor (high pressure) persists. We note
that current use of brexanolone (AlloP) for postpartum depression involves
a 60-hour infusion in which the dose is escalated to a high level observed in
pregnancy (approximately 100 nM) and maintained at that level for 28 hours
before tapering off by the end of infusion (Meltzer-Brody and Kanes, 2020).
Another NAS, zuranolone, is administered orally as a single, 30–50 mg daily
dose (Gunduz-Bruce et al., 2019; Deligiannidis et al., 2021). Levels achieved
by these steroids and duration of exposure at high levels in key brain regions
may be important in determining clinical efficacy, and high doses may be
required for maximal results, based on studies in the retina. It is also intriguing
that even transient and perhaps intermittent exposures to GABAergic NAS can
have persisting effects both in the glaucoma model and in humans with major
depressive syndromes. These observations make it important to understand
the longer-term effects of NAS following transient exposures; studies in the
retina can help this effort based on results to date.
6. The enantiomer of AlloP is an intriguing pharmacological tool, providing
unexpected neuroprotection via the cellular mechanism of autophagy.
Neuroprotection by ent-AlloP does not involve effects on GABA-A receptors
and may thus obviate certain side effects of AlloP including sedation and
loss of consciousness, perhaps allowing administration of higher doses.
Metabolism of ent-AlloP and other enantiomeric steroids will likely differ
from AlloP and possibly contribute to longer-lived effects. Side effects of
enantiomeric neurosteroids are presently unknown. A diagram of the roles of
endogenous and exogenous AlloP in the studies described is shown in Figure
3. We also note that in our in vivo glaucoma model (Ishikawa et al., 2021;
2022) and in a model of developmental neurodegeneration (Langmade et
al., 2006), both AlloP enantiomers provide neuroprotection following a single
administration that persists for weeks in rodents, while having no effect on
the causative mechanisms that underlie neuropathology.

Future Directions in Neurosteroid Pharmacology
Neuroprotective effects of both endogenous and exogenous AlloP in the
retina are unequivocal. Future studies are required to define the full
mechanisms by which neurosteroids produce their protective effects
including the role of GABA-A receptors and alternative targets. It is presently
unclear how AlloP and its enantiomer stimulate autophagy, but it is clear that
GABA-A receptors are not the entire story, particularly for ent-AlloP. Based
on work with AlloP analogues that are photoaffinity labels, both endogenous
and exogenously applied NAS interact with several known intracellular
targets. These steroids interact strongly with Golgi and this interaction, as
well as intracellular and membranous accumulation, is not enantioselective
(Jiang et al., 2016). Specific intracellular targets identified to date include
the microtubule protein, β-tubulin, at Cys-354 (Chen et al., 2012), and the
mitochondrial proteins voltage-dependent anion channel-1 and -2 (VDAC) at
Glu-73 of VDAC-1 along with four additional sites (Darbandi-Tonkabon et al.,
2003, 2004; Budelier et al., 2017; Cheng et al., 2019). The site on β-tubulin
is shared by colchicine, and the VDAC-1 sites are shared with cholesterol
(Budelier et al., 2019). These are potentially important intracellular targets
that could play a role in neuroprotection, but their roles in effects of NAS are
still undefined. Earlier studies indicated no role for VDACs in GABA-A receptor
effects of NAS or anesthesia (Darbandi-Tonkabon et al., 2004) and NAS do not
alter gating of VDAC-1 (Cheng et al., 2019). Ongoing work with photoaffinity
labels will no doubt identify other targets.
Going forward, it will be important to define other mechanisms that
contribute to homeostatic and protective effects of NAS. In particular,
neuroinflammation is a mechanism contributing to the pathogenesis of
neuropsychiatric illnesses including retinal disorders. Increasing evidence
indicates that NAS, and AlloP in particular, have anti-inflammatory effects
that may be important for therapeutic effects (Balan et al., 2019, 2021).
Other potential contributors could include effects on cellular stress responses
including the folded protein response and integrated stress response.

Autophagy interacts with integrated stress response, making this an intriguing
potential target (Kroemer et al., 2010). It will also be important to define
more clearly the role of GABA-A receptor modulation in the effects of AlloP
and whether the enantiomers have additive or synergistic effects when
applied in combination. It is also unknown at present whether mechanisms
other than GABA-A receptors contribute to psychotropic actions.
This review has focused almost exclusively on AlloP and its enantiomer.
While AlloP is a major cholesterol-derived neuromodulator, a host of
other steroids are produced in the retina and brain (Guarneri et al., 2003;
Belelli and Lambert, 2005). Some of these agents have unique properties
including effects on other ion channels, receptors, and intracellular targets.
Additionally, the class of side chain oxidized derivatives of cholesterol
(oxysterols) are also neuromodulators with 24S-hydroxycholesterol (24SHC) being the major metabolite of cholesterol in the brain (Sun et al., 2016).
24S-HC has multiple effects including potent and effective PAM activity at
NMDA receptors (Paul et al., 2013). This oxysterol has complex effects on
neurons including bidirectional effects on neurotoxicity. In some studies,
24S-HC fosters neurodegeneration, as would be expected of an NMDAR
PAM, while in other studies this oxysterol is neuroprotective (Sun et al.,
2016). In the ex vivo glaucoma model, we found 24S-HC is neuroprotective
by mechanisms that are not yet defined. Akin to AlloP, synthesis of 24S-HC
via CYP46A1 appears to be stress-activated in response to reactive oxygen
species (Sodero et al., 2011) and plays a role in regulating autophagy (Nobrega
et al., 2019). An analogue of 24S-HC, SAGE-718, is currently in clinical trials as
a cognitive enhancer in Huntington’s, Parkinson’s and Alzheimer’s diseases.
Another oxysterol, 25-hydroxycholesterol is also intriguing as a modulator
of neuroinflammation, and is synthesized in the brain primarily in microglia
(Wong et al., 2020; Izumi et al., 2021); 25-hydroxycholesterol also has weak
partial agonist PAM effects on NMDA receptors and can serve as a functional
inhibitor of 24S-HC (Linsenbardt et al., 2014).
In summary, studies in the retina clarify some of the protective mechanisms
of AlloP and offer potential to identify other important effects going
forward. It also appears that we are presently only scratching the surface
of cholesterol-derived modulators and their potential roles as therapeutics
in neuropsychiatry, including how these modulators interact to promote
neuronal homeostasis.
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